Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Kaeren, if that is true then that is a good spot. Either way I hadn't actually read that initially into the RNS. May have a material impact on Q4 earnings, NOT may have a negative impact on Q4 earnings. Whatever the situation is, and again much speciation, I agree with many shareholders that communication needs to improve. A certain ammount of guesswork is always going to be the case, and I still appreciate this companies many achievements, but respect the shareholders please BOD. You could tell us sooooooo much more.
For many long term holders who have been here through thick and thin, we have been through rough times before. Anyone remembering early May through to early September. Depressing as hell, then THE JUMP. When it goes it goes, it is the same on the upward curve. You may be thinking well we were in a different position then. This is true, since then we have expanded an international framework, considerable sales and cash in the bank. I still have faith, tho admittedly I agree they need to work on the wording of their RNSs. I am ready for the next chapter, medication at hand. Good luck to all and remember, paper losses only at this point unless you sold.
Well if that is the case and under the contract they can bill for £ 150m minimum contract value then we can expect a further £23m of income.
An added bonus...
To me there is an issue with what we are all puzzling 150mm guarenteed contract. We se DHSc invoices
Sep 1.286mm
Oct 33.322 mm
Nov 92.374mm
Total 126.984 km
In neither the update on the 29th Jan nor the update on the 9th April does it state 150mm received from DHSC there is a shortfall of 23mm. We are told monies in Jan Feb and March are for Promate this is after completion of phase one. Therefore does this mean the figures for year end 2020 include higher international sales and that the dispute between the parties revolves around this 23mm. Thus meaning it is 23mm Mullis expected but would have been in addition to the figures already reported .
I believe the comments re lower than expected international sales is down to the mainly UK focus in 2020 and need to deliver successfully and on time to the DHSC. The headcount in 2020 matched that of a pioneer in this field. Now our product range has grown alongside the enduring pandemic, plus the companies long term strategic growth plans the recent increase in headcount especially so many high level BD roles should enable contracts to be won in international markets.
Like others I am sitting on a huge paper loss with money our family can't afford to lose so have to keep the faith. As an accountant having read Blackbirds's blog earlier the figures to be don't stack. Surely common sense will kick in and our true value will shine through. If SP doesn't rise quickly can't see how we can avoid a T/O. Mixed feelings on this route as we could be truely undervalued. GLA
Maybe it is my desperation to see positive days ahead but i
@Hydra31
Answer in two parts:-
1. Boots on the ground is obviously a material help but I see the bulk of growth being Stateside going forwards. The private sector hospital business out there is just ginormous. Bottom line is they have good network being built out there and our man in New York is a major heavy weight. Only takes one decent sized order here and transforms the business outlook yet again.
2. Its all about ROI really. Going forward based on what they just declared for Q1 ex DHSC will result in the region of £ 160m EBITDA for this year. Market Comparisons: -
* Hologic are set to acquire a PCR maker for equivalent of £580m this company made £30.6m in revenue for the YEAR !!! so paying 18x revenue. We just delivered £73m for the QUARTER!!!
* Oxford Bio is listing at £5 - £7 bn Value yet delivered £ 52m Revenue and £ 72m loss.
We sit at under £300m market cap tonight, you make your own calls.
GLA
Even if you said Germany, USA and Middle East were our only other proper customers currently.... £12million a month is paltry with what is being spent on testing in those countries. I don’t know if this is a good thing as it means we have plenty of market to go at or if it exposes a flaw in our approach. Can you sell technical products in a highly competitive marketplace, effectively through distributors. Or do you need boots on the ground to win hearts and minds?
Supplying to 140 countries to me means they have at one time supplied these countries with something,
not, they supply these countries every month with something ;)
Looking back to the full year announcements I remember being quite disappointed with the revenue and making the assumption that over seas sales must be higher than we were expecting.... now we have a better idea of DHSC spend... £60 mill between April and October, £150 mill between October and December and £36 mill in quarter 1 (jan-March)
Based on this it would mean rest of world sales in 2020 are 277- 210 = 67 million. Average of £7 million a month between April and October. In quarter 1 we have 36 million or £12 million average. 70% growth
Given that the future share price is now going to be decided by the ability to grow these revenues out, what are peoples thoughts on that progress and is it sustainable. Whilst 70% growth in great, can’t help feel disappointed with the numbers. It’s the height of the pandemic and our supply to 140 countries is resulting in just £12 million a month. That’s about 10,000 tests per country per month. Pathetic really. We might have a great distribution network but it doesn’t sound like they are selling our products effectively.